Literature DB >> 27099572

Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach.

Namita Singh1, Marla C Dubinsky1.   

Abstract

Therapeutic drug monitoring (TDM) is the clinical practice of measuring drug concentrations or metabolites to attain a targeted concentration in a patient's bloodstream, thereby optimizing individual dosage regimens. With the well-established knowledge of the relationship of the genetic variability of thio-purine metabolism driven by the thiopurine S-methyltransferase pathway, and the recent data supporting pharmacokinetic variability and immunogenicity with anti-tumor necrosis factor (anti-TNF) therapies, TDM has emerged as a necessary mechanism to enhance drug efficacy. This article reviews data describing the relationship between drug concentrations and outcomes, including the achievement of a sustained and durable remission. The effect of antidrug antibodies on drug efficacy and toxicity is also examined. Furthermore, we describe different assays that are used for measuring these drug and antibody concentrations, including the advantages and pitfalls of these tools. An algorithm is proposed for clinical practitioners to utilize TDM in patients who are losing clinical response to anti-TNF therapy. A proactive, rather than reactive, approach to TDM of anti-TNF agents is supported by emerging data and will provide practitioners with the tools needed to optimally treat young inflammatory bowel disease patients.

Entities:  

Keywords:  Inflammatory bowel disease; immunogenicity; infliximab levels; infliximab trough concentrations; pharmacokinetics; therapeutic drug monitoring; thiopurine metabolites

Year:  2015        PMID: 27099572      PMCID: PMC4836578     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  48 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

4.  Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.

Authors:  O Pozler; J Chládek; J Malý; M Hroch; P Dědek; M Beránek; P Krásničanová
Journal:  J Crohns Colitis       Date:  2010-08-24       Impact factor: 9.071

5.  Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.

Authors:  C Y Ooi; T D Bohane; D Lee; D Naidoo; A S Day
Journal:  Aliment Pharmacol Ther       Date:  2007-04-15       Impact factor: 8.171

6.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; H Hildebrand; U Fagerberg; S Almer
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

9.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

10.  Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Matthieu Allez; Jean-Louis Dupas; Olivier Dewit; Geert D'Haens; Yoram Bouhnik; Gerald Parker; Bosny Pierre-Louis; Xavier Hébuterne
Journal:  Clin Gastroenterol Hepatol       Date:  2013-11-01       Impact factor: 11.382

View more
  2 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.

Authors:  Amy Hemperly; Niels Vande Casteele
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

2.  Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease.

Authors:  Jennifer Hellmann; Renee K Etter; Lee A Denson; Phillip Minar; Denise Hill; Dana M Dykes; Michael J Rosen
Journal:  Pediatr Qual Saf       Date:  2021-05-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.